Luliskora Cream contains Luliconazole 1% w/w, an imidazole antifungal agent indicated for the topical treatment of superficial fungal infections of the skin. Luliconazole exhibits broad-spectrum activity against dermatophytes, yeasts, and molds by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This cream is primarily used to manage conditions such as tinea corporis, tinea cruris, and tinea pedis caused by susceptible fungal pathogens. The formulation allows for effective penetration into the stratum corneum, ensuring targeted antifungal action with minimal systemic absorption. Luliskora Cream is typically applied once daily to the affected area and surrounding skin for a duration prescribed by a healthcare professional, generally ranging from one to two weeks depending on the severity and type of infection. It is well tolerated, with adverse effects limited mostly to mild local reactions such as burning, itching, or irritation at the application site. Luliskora Cream should be used with caution in patients with known hypersensitivity to luliconazole or any cream excipients. Proper hygiene and adherence to the prescribed treatment regimen are essential to achieve optimal therapeutic outcomes and prevent recurrence.